面向临床研究的基因测序项目的设计原则、管理流程与质量控制标准

doi:10.3969/j.issn.1673-5765.2022.03.003

摘要/Abstract

摘要：

目的开发并搭建适用于临床研究的基因测序项目管理和数据质量控制流程，为基于队列的组学分析、疾病机制探索、药物靶标开发等提供技术保障。

方法基于生物医学研究中小样本的测序流程，参考国际大规模测序队列，形成面向临床研究的基因测序项目框架。从样本处理、测序数据生成、生物信息学分析、项目的质量保证、数据安全与生物样本安全等多个环节，进行管理流程的搭建和优化。

结果确定了面向临床研究的基因测序项目的设计原则，搭建了系统性管理流程。通过将此流程应用于中国国家卒中登记Ⅲ（China national stroke registry-Ⅲ，CNSR-Ⅲ）队列，建立了数据质控标准，包括DNA提取和文库制备质控、测序和遗传变异鉴定质控、样本临床信息推断质控和基因检测数据的相互验证等。

结论在临床研究中将基因检测纳入试验设计，并采用标准化的管理流程、数据分析方案和统一的质控标准，能够满足科学研究的可扩展性、可重复性、可溯源性的需求。本研究搭建的基因测序项目管理流程和质控标准已在CNSR-Ⅲ队列上验证成功，可以作为其他临床研究中此类项目的参考标准。

文章导读： 本研究搭建了一套基因测序项目框架，在中国国家卒中登记Ⅲ队列上应用成功，可以为其他临床研究中基因测序项目的管理与质量控制提供参考与借鉴。

关键词: 基因检测; 全基因组测序; 临床研究; 质量管理

Abstract: Objective To develop the standards for clinical research-oriented gene sequencing project management and data quality control pipeline, and provide technical support for cohort-based omics analysis, disease mechanism exploration, and drug target development. Methods Based on the gene sequencing protocol of small samples in biomedical research and with reference to international large-scale sequencing cohorts, a clinical research-oriented gene sequencing project framework was constructed. The management process was designed and optimized in terms of multiple procedures, such as sample processing, sequencing data generation, bioinformatics analysis, project quality assurance, data safety and biobank safety. Results The rationale of clinical research oriented-gene sequencing projects was determined, and the management pipeline was established. By applying this pipeline to the China national stroke registry-Ⅲ (CNSR-Ⅲ) cohort, data quality control standards were established, including DNA extraction and library preparation standards, sequencing and genetic variants identification standards, sample clinical information inference standards, mutual verification of genetic testing data standards, etc. Conclusions The application of genetic testing in clinical research, with its standardized

management pipeline, data analysis, and unified quality control standards, could meet the scalability,

traceability and reproducibility requirements of scientific research. The gene sequencing project management and data quality control standards established in this study has been successfully verified in the CNSR-Ⅲ cohorts, and can be used as a reference standard for gene sequencing projects in other clinical studies.

Key words: Genetic testing; Whole genome sequencing; Clinical research; Quality control

刘阳, 许喆, 程丝, 石延枫, 林金嬉, 孟霞, 姜勇, 李昊. 面向临床研究的基因测序项目的设计原则、管理流程与质量控制标准[J]. 中国卒中杂志, 2022, 17(03): 227-235.

LIU Yang, XU Zhe, CHENG Si, SHI Yanfeng, LIN Jinxi, MENG Xia, JIANG Yong, LI Hao. Clinical Research-Oriented Gene Sequencing Projects: Rationale, Management and Quality Control Standards[J]. Chinese Journal of Stroke, 2022, 17(03): 227-235.

参考文献

[1] HÖGLUND J，RAFATI N，RASK-ANDERSEN M，et al. Improved power and precision with whole genome sequencing data in genome-wide association studies of inflammatory biomarkers[J/OL]. Sci Rep，2019，9（1）：16844[2021-12-01]. https://doi.org/10.1038/s41598-019-53111-7.
[2] KOBOLDT D C. Best practices for variant calling in clinical sequencing[J/OL]. Genome Med，2020，12（1）：91[2021-12-01]. https://doi.org/10.1186/s13073-020-00791-w.
[3] CASPAR S M，DUBACHER N，KOPPS A M，et al. Clinical sequencing：from raw data to diagnosis with lifetime value[J]. Clin Genet，2018，93（3）：508-519.

[4] LIGHTBODY G，HABERLAND V，BROWNE F，et al. Review of applications of high-throughput sequencing in personalized medicine：barriers and facilitators of future progress in research and clinical application[J]. Brief Bioinform，2019，20（5）：1795-1811.
[5] HWANG K B，LEE I H，LI H，et al. Comparative analysis of whole-genome sequencing pipelines to minimize false negative findings[J/OL]. Sci Rep，2019，9（1）：3219[2021-12-01]. https://doi.org/10.1038/s41598-019-39108-2.
[6] Cancer Genome At la s Resea rch Network，WEINSTEIN J N，COLLISSON E A，et al. The cancer genome atlas pan-cancer analysis project[J]. Nat Genet，2013，45（10）：1113-1120.
[7] CAO Y N，LI L，XU M，et al. The ChinaMAP analytics of deep whole genome sequences in 10 588 individuals[J]. Cell Res，2020，30（9）：717-731.
[8] GILLY A，SUVEGES D，KUCHENBAECKER K，et al. Cohort-wide deep whole genome sequencing and the allelic architecture of complex traits[J/OL]. Nat Commun，2018，9（1）：4674[2021-12-01]. https://doi.org/10.1038/s41467-018-07070-8.
[9] ERIKSON G A，BODIAN D L，RUEDA M，et al. Whole genome sequencing of a healthy aging cohort[J]. Cell，2016，165（4）：1002-1011.
[10] LEEK J T，SCHARPF R B，BRAVO H C，et al. Tackling the widespread and critical impact of batch
effects in high-throughput data[J]. Nat Rev Genet，2010，11（10）：733-739.
[11] GOHW W B，WANG W，WONG L. Why batch effects matter in omics data，and how to avoid them[J]. Trends Biotechnol，2017，35（6）：498-507.
[12] WICKLAND D P，REN Y，SINNWELL J P，et al. Impact of variant-level batch effects on identification of genetic risk factors in large sequencing studies[J/OL]. PLoS One，2021，16（4）：e0249305[2021-12-01]. https://doi. org/10. 1371/journal. pone. 0249305.
[13] AKEY J M，BISWAS S，LEEK J T，et al. On the design and analysis of gene expression studies in human populations[J]. Nat Genet，2007，39（7）：807-808.
[14] WANG Y J，JING J，MENG X，et al. The third China national st roke regist ry（CNSR-Ⅲ）for patients with acute ischaemic stroke or transient ischaemic attack：design，rationale and baseline patient characteristics[J]. Stroke Vasc Neurol，2019，4（3）：158-164.
[15] YOHE S，THYAGARAJAN B. Review of clinical next-generation sequencing[J]. Arch Pathol Lab Med，2017，141（11）：1544-1557.
[16] CHENG S，XU Z，LIU Y，et al. Whole genome sequencing of 10K patients with acute ischaemic stroke or t ransient ischaemic at tack：design，methods and baseline patient characteristics[J]. Stroke Vasc Neurol，2021，6（2）：291-297.
[17] CHEN S F，ZHOU Y Q，CHEN Y R，et al . Fast panul tra-fastall-in-one FASTQ preprocessor[J/OL]. Bioinformatics，2018，34（17）：i884-i890[2021-12-01]. https://doi.org/10.1093/bioinformatics/bty560.
[18] KENDIG K I，BAHETI S，BOCKOL M A，et al. Sentieon DNASeq variant calling workf low demonstrates strong computational performance and accuracy[J/OL]. Front Genet，2019，10：736[2021-12-01]. https://doi.org/10.3389/fgene.2019.00736.
[19] ZHANG F，FLICKINGER M，TALIUN S A G，et al. Ancestry-agnostic estimation of DNA sample
contamination from sequence reads[J]. Genome Res，2020，30（2）：185-194.
[20] POPLIN R，RUANO-RUBIO V，DEPRISTO M A，et al. Scaling accurate genetic variant discovery to tens of thousands of samples[R/OL]. BioRxiv，2018：201178[2021-11-06]. https://doi.org/10.1101/201178.
[21] CHANG C C，CHOW C C，TELLIER L C，et al. Second-generation PLINK：rising to the challenge of larger and richer datasets[J/OL]. Gigascience，2015，4：7[2021-11-06]. https://doi.org/10.1186/s13742-015-0047-8.
[22] MANICHAIKUL A，MYCHALECKYJ J C，RICH S S，et al. Robust relationship inference in genomewide association studies[J]. Bioinformatics，2010，26（22）：2867-2873.
[23] BAMSHAD M J，SHENDURE J A，VALLE D，et al. The centers for Mendelian genomics：a new large-scale initiative to identify the genes underlying rare Mendelian conditions[J/OL]. Am J Med Genet A，2012，158A（7）：1523-1525[2021-11-06]. https://doi.org/10.1002/ajmg.a.35470.
[24] UK10K Consortium，WALTER K，MIN J L，et al. The UK10K project identifies rare variants in health and disease[J]. Nature，2015，526（7571）：82-90.